RDIF在墨西哥，巴西和印度建立Sputnik V疫苗网络
发表于09/16/2020
俄罗斯直接投资基金（RDIF）
和
雷迪博士实验室有限公司（雷迪博士）是一家总部位于印度以外的全球制药公司，
已同意在印度进行人造卫星V疫苗的临床试验和分销。
根据新闻稿，“经印度监管机构批准，
RDIF：
应向雷迪博士提供1亿剂疫苗。
人造卫星V疫苗，
该药物基于经过充分研究并具有公认安全性的人腺病毒载体平台，目前正在针对冠状病毒大流行进行临床试验。
Deliveries :
could potentially begin in late 2020 subject to completion of successful trials and registration of the vaccine by regulatory authorities in India.
The agreement between RDIF and Dr Reddy’s :
reflects the growing awareness of countries and organizations to have a diversified anti-COVID vaccine portfolio to protect their populations.”
Earlier on September 11, 2020,
RDIF :disclosed a cooperation agreement with the State of Bahia (Brazil), through its Health Secretariat, to supply up to 50 million doses of Sputnik V.
On September 9,
RDIF and the pharmaceutical company Landsteiner Scientific
announced an agreement for the supply of 32 million doses of the Russian Sputnik V vaccine to Mexico.-SWFI